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Nanoparticle(NP)-based materials have breakthrough applications in many fields of life, such as in engineering, communications
and textiles industries; food and bioenvironmental applications; medicines and cosmetics, etc. Biomedical applications of NPs are
very active areas of research with successful translation to pharmaceutical and clinical uses overcoming both pharmaceutical and
clinical challenges. Although the attractiveness and enhanced applications of these NPs stem from their exceptional properties at
the nanoscale size, i.e. 1–1000 nm, they exhibit completely different physicochemical profiles and, subsequently, toxicological
profiles from their parent bulk materials. Hence, the clinical evaluation and toxicological assessment of NPs interactions within
biological systems are continuously evolving to ensure their safety at the nanoscale. The pulmonary system is one of the primary
routes of exposure to airborne NPs either intentionally, via aerosolized nanomedicines targeting pulmonary pathologies such as
cancer or asthma, or unintentionally, via natural NPs and anthropogenic (man-made) NPs. This review presents the state-of-the-
art, contemporary challenges, and knowledge gaps in the toxicological assessment of NPs interactions with the pulmonary sys-
tem. It highlights the main mechanisms of NP toxicity, factors influencing their toxicity, the different toxicological assessment
methods and their drawbacks, and the recent NP regulatory guidelines based on literature collected from the research pool of
NPs interactions with lung cell lines, in vivo inhalation studies, and clinical trials.
Keywords: Pulmonary nanotoxicology   ; nanoparticles toxicity   ; inhalation of nanoparticles   ; pulmonary delivery   ; aerosolized 
drug delivery 
1. Introduction
NPs are fueling the development of a novel class of medicines retaining engineered NPs for various theranostic appli‐
cations such as analytical nano-devices, novel nanotherapeutics, drug delivery and targeting nanocarriers, tissue engi‐
neering, clinical, and toxicological applications, and all these applications are under the umbrella of Nanomedicine.
Thanks to their nanosize, NPs can easily penetrate the cellular barriers and migrate to the site of action and cross 
different types of biological barriers (Samaridou and Alonso 2018). In addition, NPs can enhance pharmaceutical 
properties such as drug stability, dissolution rate, and bioavailability; especially important for poorly soluble and hy‐
drophobic drugs (Merisko-Liversidge and Liversidge 2008). NPs have very versatile capacities to encapsulate differ‐
ent types of molecules; not only drugs, but also macromolecules (Depreter, Pilcer, and Amighi 2013; Tawfeek et al. 
2013; Gaggar et al. 2016), biopharmaceuticals (Kunda et al. 2015; Chauhan and Sood 2016), nucleic acids and gene 
therapeutics (Rudolph et al. 2005; Babincova and Babinec 2006; Kim et al. 2014; Yan et al. 2017). They efficiently
1
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allow for multidrug or combinational therapy targeting (Wang et al. 2016; Costa-Gouveia et al. 2017; Zhang et al. 
2017; Yan et al. 2018) achieving synergistic, or multi-targeting, or theranostic applications. Functionalized NPs can 
deliver the active substance intracellularly (Medina et al. 2009 Sangtani et al. 2018). Furthermore, NPs could be 
modulated with mechanisms to target only the diseased tissue or cells, either passively, through the enhanced per‐
meability and retention effect (EPR) (increased local blood supply tends to pool the NPs as in case of tumor sites), or 
actively, through targeting molecules like antibodies (here the tumor cells selectively intake the NPs) (Zimmer 2002; 
Zamboni et al. 2012). In addition, NPs can be equipped with mechanisms to allow the control of drug release, i.e. 
sustained or slow release, pulsatile or stimuli-responsive release (Kalaydina et al. 2018; Tan et al. 2018; Zhou, Wang, 
and Li 2018. The release profile from these carriers can be tuned by enhancing their physicochemical proper‐ties. 
These mechanisms would boost the drug bioavailability at the site of action, bypassing the hepatic metabolism, 
lowering the off-target systemic side-effects and improving the therapeutic efficacy, patient compliance, and health 
outcomes. NPs delivered systemically showed better circulatory distribution profiles and less aggregations compared 
to microparticles (De Jong and Borm 2008; Mansour, Rhee, and Wu 2009; Kalaydina et al. 2018).
NP fabrication based on natural or synthetic materials provide tissue safety and biocompatibility. Recently, biode‐
gradable polymers appeared very attractive for pharmaceutical applications, fueling the development of drug delivery 
systems due to their biocompatibility, biodegradability, and ease of fabrication and functionalization. More details 
about the different nanocarriers, their formulation processes and different excipients used to formulate NPs for lung 
delivery could be found in these sources (Pilcer and Amighi 2010; Vilar, Tulla-Puche, and Albericio 2012; Iyer, Hsia, 
and Nguyen 2015; Gaul et al. 2018; Chavda 2019). Although nanomedicines are designed to enhance the drug effica‐
cy and reduce its toxicity, potential risks and unique challenges may occur due to the exceptional properties of their 
engineered nanomaterials. This has lead to the development of a new branch of science, known as Nanotoxicology, to 
understand, determine, and regulate the main factors underlying the toxicological concerns of nanomaterials (Donald‐
son et al. 2004; Lombardo, Kiselev, and Caccamo 2019).
With the increased application of nanomaterials in various fields of life, human exposure to NPs is raising many 
concerns. Due to their novel properties, there is a knowledge gap, still to be fulfilled, about their dynamics in the 
environment and in biological systems, and the safety of exposure in both cases. The pulmonary system is a biologi‐
cal system that is a primary route for NPs exposure, as airborne or aerosolized (particles either liquid or solid that can 
be suspended in air). The pulmonary system is actively targeted with pharmaceutical NP aerosols to treat either local 
or systemic pathologies. However, unintentional exposure to NPs in environmental and occupational settings, as well 
as from NP-based products, has been reported in various research studies and regulatory reports (Steinhäuser and 
Sayre 2017).
There are many official, and non-official, regulatory bodies to control the industrial and pharmaceutical use of 
nanomaterials. The challenges here are the lack of standardization specifically addressing the NPs. Details regarding 
these regulatory bodies can be found in these sources (Abdolahpur Monikh et al. 2018; Coty and Vauthier 2018; La‐
mon et al. 2019).
NPs testing is commonly achieved via two complementary methods prior to human clinical trials, namely in vitro 
and in vivo approaches. The in vitro approaches use different cell lines and expose them to a range of NPs concentra‐
tions, detecting various endpoints and mechanisms. The in vitro approaches provide initial screens, are less ethically 
problematic, less costly, and offer mechanistic insight to understand the NP interaction with the target cells. Although 
many researchers argue that the static nature of this exposure lacks the in vivo dynamics of NP exposure, many exam‐
ples of successful correlations have proven that in vitro approaches can translate to in vivo conditions and, yet, there 
is capacity for improvement. Promising approaches are being developed and validated to increase the sensitivity and 
the in vivo translation of the in vitro models, such as ex vivo models, dynamic organoids or miniaturized body-on-chip 
systems, and in silico models (Myatt et al. 2018; Oberdorster and Kuhlbusch 2018; Rothen-Rutishauser, Bourquin, 
and Petri-Fink 2019).
2. Pulmonary route for nanoparticle drug delivery
Respiratory diseases occupy the top four main causes associated with global mortality; chronic obstructive pulmo‐
nary disease (COPD), lower respiratory tract infections, lung cancer, and Tuberculosis (WHO). Together they repre‐
sent the cause of death in one-sixth of global deaths, which is expected to increase to one fifth in the next few years.
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Respiratory morbidity accounts for one-tenth of disability-adjusted life-years (DALYs), which is a universal metric 
used to measure the loss of the productive years in the life of the affected persons. According to the European Lung 
White Book, (2013), respiratory diseases are responsible for 66% of a million deaths, and more than 6 million cases 
of hospitalizations accounting for more than forty million days of bed-redden patients each year in Europe (Society 
2013). The research pools are actively trying to tackle the respiratory problems with novel approaches, i.e. NP appli‐
cations, intensifying its abilities for local and systemic drug delivery purposes based on its immense health implica‐
tions and the unique advantages that can be offered.
The respiratory system is a complex vital organ that has two structurally different regions; conducting (upper) and 
respiratory (lower) part (Figure 1(A)) (Stocks and Hislop 2002; Osman et al. 2018). The conducting airways start 
from the mouth/nose, comprising the trachea and extending to approximately 17 branching times until reaching the 
respiratory bronchioles with progressive narrowing. The lining epithelium is pseudo-stratified ciliated epithelium 
with tight junctions, with abundant mucous glands, which secret mucous that is responsible for the air filtration, hu‐
midity, and acts with the motile cilia to provide mucociliary clearance/escalator (Figure 1(B)). The epithelial thick‐
ness is approximately 60 µm lined with a thick mucus layer with a cover layer of a lung surfactant (Kunda et al. 
2013). Diseases affecting the conducting airways, i.e. asthma, CF, COPD, impair the respiratory functions by devel‐
oping pulmonary hypertension and aggravating the bronchoconstriction and congruently, impairing the efficiency of 
NPs drug delivery to the lungs or the drug absorption. The respiratory airways are distal to the terminal bronchioles 
consisting of the respiratory bronchioles and alveolar ducts ending in alveolar sacs (18-25 generations). The lining 
epithelium consists of two main cell types (Figure 1(C)): Alveolar type I, which is the main cell, involved in the al‐
veolar air-blood barrier, and the alveolar cell type II, which is responsible for secreting lung surfactant. It has a ple‐
thora of immune cells rich in wandering macrophages that are responsible for macrophage clearance eliminating par‐
ticle mechanisms (Gordon and Read 2002 Byrne et al. 2015). The lining epithelium is very thin, 0.1-0.2 µm, with a 
fluid lining thickness of 70 nm. The alveolar epithelium has tight and gap junctions and shows high permeabil‐ity. 
Diseases affecting the respiratory region are very common debilitating conditions, such as infections, tuberculo‐sis, 
emphysema, lung fibrosis, lung cancer, acute distress and pulmonary edema. These conditions might limit the 
efficiency of NP aerosol delivery.
Figure 1. (A, B, C) Lung structure and epithelial differences. Reprinted with permission from reference (Osman et al. 2018).
2.1. Pharmacological advantages and limitations of drug delivery via the lungs
The pulmonary route for drug delivery provides many advantages and is challenged with some limitations sum‐
marized in Table 1. The respiratory part is considered ideal for therapeutic aerosols absorption for many reasons,
most saliently, wide surface area, thin lining epithelium, and high permeability. The limitations are the deepest and
narrowest areas of the lung, presence of the effective clearance mechanisms, internal humidity, and progressive
branching and narrowing impacting the drug away from the target (Rangaraj, Pailla, and Sampathi 2019).
Table 1. Advantages and limitations of the pulmonary drug delivery, and recent strategies to overcome these limitations.
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Advantages of the pulmonary route
drug administration
Limitations of the pulmonary route Strategies to overcome the limi‐
tations
• The wide surface area
of the respiratory part;
80–100 m2 other




3 m2, allows for
greater contact with
the inspired air for gas
exchange (Patton
1996)
• The pulmonary airways
undergo progressive nar‐
rowing that traps the
particle away from the
deep alveoli.
• NPs size con‐
trol, the smaller











• The respiratory lining
epithelium is reduced
to submicron thick‐
ness (0.2 µm) from
approximately 60  in
the conducting areas,
accompanied with
thinning of the fluid
lining layer as well
(from 8 µm to 70 ).




away from the respirato‐














um is densely vascu‐
larized (5 L/min) with
fast drug distribution
and circulation (Hu,
Jiao, et al. 2013).
• The conducting region
has very think epithelial
lining (60 µm) covered
with a thick mucus layer
and lung surfactant, rep‐
resenting a challenge for
the inhaled particles to
penetrate, and aiding in
the particle agglomera‐





















Advantages of the pulmonary route
drug administration
Limitations of the pulmonary route Strategies to overcome the limi‐
tations




cules, water and mac‐
romolecules suiting
the air exchange re‐
quirements and aids in
NP targeting topical
or systemic sites. Its
permeability to differ‐







• The epithelial tight junc‐
tions prevent drug mole‐












and lowering dose fre‐
quency and decrease
the potential side ef‐
fects (Chandel et al.
2019).
• The effective mucocili‐




• The mucous production
in healthy individual is
10–20 ml a day and the
ciliary velocity is 1–
20 mm per min from the
peripheral towards the
trachea (Rangaraj, Pail‐










Advantages of the pulmonary route
drug administration
Limitations of the pulmonary route Strategies to overcome the limi‐
tations
• The high pulmonary
bioavailability stems
from the epithelial
properties and has a
significant protease
inhibitory activity, no




ance effect, and it also
avoids the gut irrita‐
tion, irritable bowel
and food/oral drug in‐
teractions. That al‐
lows for fast absorp‐
tion, rapid onset of ac‐
tion, and efficient
drug delivery (Patton
1996; Labiris and Do‐
lovich 2003).




2005, Byrne et al. 2015),
that could be beneficial
to stimulate the immune
response for the vaccina‐
tion (Chono et al.
2006,Kleinstreuer,
Zhang, and Donohue









































• Pulmonary system is af‐
fected by many diseases
that decrease the airflow
limiting the efficiency of





be used to ad‐
just with the
lung conditions
• NP toxicity and Inflam‐
mation: NPs should be 
carefully investigated to 
be biocompatible and bi‐
odegradable materials as 
to exclude any adverse 














2.2. Aerosol drug delivery of nanoparticles to the lungs
Burgeoning interest has manifested in NP drug delivery to the lungs via aerosols. NP aerosols have superior ad‐
vantages which include the benefits derived from the advantages of the pulmonary route characteristics: the ability to
localize the drug at the site of action with longer retention by preventing its systemic distribution and elimination,
achieving a uniform NP distribution and increasing the drug solubility. This is combined with the advantages offered
by NP formulation characteristics and can be used for systemic drug delivery resulting in improvement of the clinical
outcomes (Takenaka et al. 2001; Hohenegger 2010). The USFDA has approved a liposomal (ARIKAYCE®) amika‐
cin suspension for the treatment of Mycobacterium avium complex (MAC) lung disease via nebulization as the first
NP-drug aerosol delivery (Insmed 2019). A list of aerosolized nanomedicines either approved for lung delivery or
still in the preclinical or clinical stages is provided in Table 2.
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Cyclosporine Lipososmes Lung transplant
rejection





























Gelatin NPs Cancer lung Preclinical in vitro and in vivo
lung study


























NSCLC in vivo lung study (Jyoti et al. 2015)
Paclitaxel PEG5000-DSPEmi‐
celles
Lung cancer In vitro and in vivo animal
study
(Gill, Nazzal, and Kad‐
doumi 2011)













Quercetin PLGA NP coated
with magnetic
(Fe3O4) NPs
Lung cancer In vitro and in vivo studies (Verma et al. 2013)
Losartan and telmi‐
sartan
Polystyrene NPs Lung cancers In vivo animal study (Godugu et al. 2013)













In vivo animal study (Kaminskas et al. 2014)
Gene delivery: Akt1
siRNA
PEI NP Lung Cancer/
Metastases
Preclinical in vivo assay (Ray, Mandal, and Mitra
2015)
Ricin vaccine Liposomes Ricin toxicity Preclinical in vivo assay (Smallshaw, Richard‐






Preclinical in vivo mouse assay (Rodrigues et al. 2018)
Indomethacin, keto‐
profen
SLNP Asthma Preclinical in vivo assay (Mansour, Rhee, and
Wu 2009)


















fects in lung in
asthma






On clinic, first approved in




Insulin PLGA, PEI, Chito‐
san NP
Diabetes Preclinical in vivo assay (Hohenegger 2010)
Calcitonin PLGA-Chitosan NP Parathyroid dis‐
eases
Preclinical in vivo assay (Sung, Pulliam, and Ed‐
wards 2007)
Therapeutic peptide Calcium phosphate
NP
Heart failure Preclinical in vivo assay (Miragoli et al. 2018)
2.2.1. Nanoparticle aerosol generation and deposition into the lungs
Inhalation drug delivery is attained via respirable-sized aerosol particles. The aerosol is described as suspended
solid or liquid particles stabilized in a gaseous phase (Moraga-Espinoza, Eshaghian, and Smyth 2018). There are
three widely recognized aerosols-generating devices: Nebulizers (Corcoran et al. 2014; Wang, Li, et al. 2017), me‐
tered-dose inhalers (MDI) (Moraga-Espinoza, Eshaghian, and Smyth 2018), dry powder inhalers (DPI) (Hoppentocht
et al. 2014; De Boer et al. 2017). The mechanism of aerosol generation, advantages and limitations, indications of
each device, and the recent developments can be found in the following sources (Dolovich and Dhand 2011; Berlin‐
ski 2015; Stein and Thiel 2017; Chandel et al. 2019).
The aerosols are described by their aerodynamic diameter (AD) which is the diameter of a unit density sphere
(water droplet) having the same settling velocity in the air to the particle of interest (De Boer et al. 2002). The aero‐
sols that have an inhalable size are of an AD smaller than 10 µm and classified as coarse particles (>2 µm), fine
particle fraction (0.1–2 µm), and ultrafine particle fraction (<0.1 µm). The AD range of the pharmaceutical aerosols
is between 0.5 and 5 µm (Labiris and Dolovich 2003). A major limitation for NPs lung deposition as a dry powder is
their AD is smaller than the optimal size for aerosol deposition; 0.5–5 µm (Bisgaard, O'callaghan, and Smaldone
1999). This means the delivery of NPs as a single/monodisperse NP aerosol to the lungs is almost impossible. Many
formulations and delivery strategies are there to overcome this limitation, such as formulating NPs in a bigger carrier
as microparticle (Tsapis et al. 2002; Alfagih et al. 2015; Bohr et al. 2015; Mcbride, Price, and Muttil 2017; Wang,
Beck-Broichsitter, et al. 2017), delivering NPs aggregates either pure or with excipient carriers such as lactose or L-
leucine, or freeze-dried or pre-spray dried in large porous or hollow carriers in DPI, or delivering the NPs as micron-
sized agglomerates using nebulization/pMDI that achieves a temporary increase in their AD favoring their lung depo‐
sition (Oswald ripening). Recently, effervescent particles technology that involves spray-drying into effervescent ex‐
cipients has shown better aerosolization and faster release of NPs upon dissolution in aqueous media (Ely et al. 2007,
Azarmi et al. 2008, Al-Hallak et al. 2012). NPs drug delivery via DPI is claimed to be better than nebulization/pMDI
in being more controlled and stable spherical particles, better loading, and aerosolization performance (Hu, D, et al.
2013; Iyer, Hsia, and Nguyen 2015). The physicochemical properties of aerosol NPs represent an active area in multi-
disciplinary research as to develop physicochemical characters that are nontoxic, efficient loading and target-delivery
vehicle, safe and fit for the purpose, better aerosolization performance, stability, etc (Lewinski, Colvin, and Drezek
2008).
The deposition of inhaled particles into the pulmonary targets is known to be through the following mechanisms
either: impaction, gravitational settling, interception, and Brownian diffusion. Cationic charged particles are exposed
to another force depositing them into the airways known as electrostatic precipitation. Further details about these
mechanisms can be found in the following sources (Gaul et al. 2018 Rangaraj, Pailla, and Sampathi 2019). The NPs
aerosol deposition into the lungs is multifactorial dependent process and primarily depends on the physicochemical
properties of the NP aerosol, the aerosol generating device; including the inhalation route; oral or nasal, and carrier
medium; air (Nebulizers, DPI), or a propellant, and lastly but equally important, patient factors; the underlying pul‐
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monary pathophysiology including the respiratory volumes, breath-holding, and the severity of the lung disease
(Heyder 2004, Stein and Thiel 2017, Rangaraj, Pailla, and Sampathi 2019). These factors and their effects on the dep‐
osition are summarized in Table 3.





Effect on lung deposition
NP physicochemical characteristics
Size • 5–10 µm Aerosols impact in the upper airways
• Prone to mucociliary clearance
• 0.5–5 µm Aerosols sediment in the deeper airways
• Prone to mucociliary and macrophages clearance mechanisms
• Below 0.5 µm Aerosols undergo diffusion in the deepest airways
• Less phagocytic uptake, <200 nm are not recognized by macrophages
• More cohesive/adhesive agglomerates that difficult to be dispersed
Shape • Spherical particles are commonly employed as easier fabrication methods.
• High aspect ratio/ Fiber-like NPs deposited by interception. This was adapted from
pathological example of asbestos.
Charge • Cationic coated NPs are deposited by the electrostatic interception.
• Longer residence or membrane bound time
Density • NPs deposition in the deepest regions is inversely relate to the particle density.
• Hollow particle with lower density and larger size is better deposited than small dense
solid particles
Chemistry • Slight hydrophobic particles increase the absorption but strong hydrophobic will in‐
crease the retention time.
• Small molecular weight (MWt) hydrophilic particles will be fast absorbed to larger
molecules.
• High MWt particles are less permeable in the alveolar epithelium
Solubility • The readily soluble particles will be less prone to clearance than insoluble particles that
will be trapped either by the mucociliary or macrophage s clearance
• Poor soluble particles with size over 6 μm are cleared faster and most of deposited par‐












• The limitations (discussed in Table 1) of the normal lung structure such as airway
branching and narrowing, mucous, surfactant, epithelial barriers and clearance mecha‐
nisms, person-person variations, age related variations.
• In lung pathological conditions that affect the lung normal structure by progressive nar‐
rowing, i.e. bronchoconstriction, as in asthma, COPD, chronic bronchitis where the in‐
flamed epithelium with over secretions of mucous, aerosol deposition is altered. The air
flow speed is increased with the excessive narrowing, impacting the particles in the up‐
per airways, and the air flow will be shifted to the less affected airways that directs the
aerosol away from the diseased sites.
Inhalation
pattern
• Oral inhalation has better lung deposition than nasal route.
Airflow
velocity
• Fast air flow velocity impacts the particles away from the lower airways




• The air into the lung carries the aerosols; the flow pattern might be either laminar or
turbulent. In case of laminar flow, the deposition forces are fluid viscous forces while
in turbulent, more inertial forces and Brownian movements of molecules. Further de‐
tails can be found in (Darquenne 2012)
• Inspiratory flow rates are very critical for the aerosl generation and optimum depsotion.
Discussed wit the device section below
Humidity • The humid internal environment can affect the size of hygroscopic NPs and subse‐
quently the mechanism and site of deposition.
• Hygroscopic particles can become larger or smaller according to their chemistry
• Hygroscopic effect is considered minimal for particles below 0.1 µm
• This can be used as a technique to deposit the NPs in the deeper airways by minimizing





• Once deposited in the upper airways, the mucociliary clearance works effectively to
eliminate the deposited particles to be coughed out or swallowed to the gut.
• The mucociliary clearance efficiency is affected in a group of lung diseases as lung fib‐
rosis, CF, or ciliary dyskinesia where the mobility of the cilia is impaired and the mu‐





• NPs deposited in the alveolar epithelium will be subjected to clearance by the alveolar
macrophages
• The alveolar sac can contain up to 6 wandering macrophages continuously acting to
eliminate any foreign materials
• Soluble particles will fast evade the elimination by absorption and translocation to the
epithelium
• Particles slow low solubility or designed for controlled sustained release have longer
residence time and more prone to macrophages uptake and subsequent clearance to mu‐
cociliary region, lymphatic and RES or slowly degrading.






Effect on lung deposition
Target site • If the NPs aerosols are deposited away from the target site, it lowers the efficacy of the
treatment. Prior understanding of the disease and the disease site to target the delivery
is a must. For example, in case of asthma, it would be wisely to target a NP steroid
aerosol depositing that should be uniform all over the lung tissue to target all the in‐
flammatory cells in the respiratory tree.
• Another example, in case of infection, the site of where the infection happening is pre-
determined, i.e. in the upper or lower airways, affecting the epithelium or localizing in
the lumen.
The aerosol generating device factors
Nebulizers • Commonly used device in uncooperative patient
• FPF ranging from 60–80%
• Deliver mixes of drugs in one shot
• Effective in lower inspiratory flow 6–8 l per min
• ∼ 10% dose is deposited, various patient training techniques as to breathe deeply and
breath-holding can increase the deposition to 17%
• Main concerns are the negative effect on the formulation structure integrity, the carrier
or the drug or macromolecules might get damaged due to the nebuliation forces. New
generations of nebulizers such as vibrating mesh technologies, that deliver more uni‐
form particles that can increase the deep lung deposition and maintain the formulation
integrity are being developed and used. Further details can be found in (Chandel et al.
2019).
MDI • Commonly portable device and used by COPD, asthma patients.
• FPF can be up to 70%
• ∼20% of the dose deposited with minimal inspiratory flow rate is necessary ∼20 l/min.
• The formulation integrity is achieved with producing inhalable aerosols and using a
propellent.
• The main issue that might render the treatment unsuccessful in some patient is the lack
of coordination.
• Not suitable for delivery of high doses and long-term storage as loss of stability or deg‐
radation might happen.
• New MDI have been developed allowing less patient effort to actuate, such as Autohal‐
er® and Easybreath®; shown better lung deposition and less inspiratory volumes re‐






Effect on lung deposition
DPI • DPIs have superior advantages over the other devices based on more stable powder for‐
mulation
• DPIs are breath-actuated minimizing the lack of coordination
• DPIs might have similar deposition rate to the MDIs.
• Inspiratory flow, humidity and temperature have great effect on the DPI aerosol per‐
formance
• An inspiratory flow rate of at least 30 l/min is necessary for aerosol generation.
• Difficult use in debilitating conditions, elderly, and children
• Newer generations and further details are in the following source (Chandel et al. 2019).
2.2.2. Challenges of formulating nanoparticle aerosol for lung delivery
NPs aerosol delivery is still not well established and faces many challenges. Apart from the toxicological poten‐
tials of the nano-specific components, the aerosolized formulations may contain other stabilizers or emulsifiers that 
were used either during the fabrication process or in the final product that must be considered as part of their safety. 
The aerosol deposition is not a straightforward process and needs extensive optimization of the formulation. The dis‐
eased lung condition that might add more difficulty in achieving the aimed deposition capacity. The loading efficien‐
cy and the stability of the loaded active agent must be worthwhile. Translation from benchtop to the clinics is not 
easy with challenges to be considered, i.e. the dose- and dosage-form defining problems (Scherließ and Etschmann 
2018, the shelf-life, the scalability, the ease and safety of the use, and the last but not the least is the cost (Iyer, Hsia, 
and Nguyen 2015).
3. Unintentional pulmonary exposure to nanoparticles
Unintentional exposure to NPs covers any exposure to NPs not intentionally planned such as NPs emitting from
natural sources (such as volcanos, soot and fire ashes). Unintentional exposure to anthropogenic NPs can occur in
occupational settings (during manufacturing processes using raw NPs materials or generating them as secondary by-
products), and recently increased in-market consumer products that are based on NPs. Table 4 provides a non-inclu‐
sive list of examples of NPs that can be found as airborne from occupational settings and/or from consumer products
(Zhang et al. 2015, Foss Hansen et al. 2016, Kuhlbusch, Wijnhoven, and Haase 2018). This exposure can happen via
different routes of entry, such as the skin and oral route, but inhalation exposure to the airborne NPs is very concern‐
ing due to the vulnerability and inevitable nature of inhalation with the inherent ability of NPs to be easily suspended
in air (Steinhäuser and Sayre 2017).
Table 4. Examples of NPs that can be found airborne in occupational settings and/or from consumer based products.
NPs Occupational and/or consumer exposure
Ag Textiles, Electronics, food packaging, medical devices, antimicrobial and disinfectant
sprays, refrigerators and air humidifiers
Iron NPs (Fe2O3, Fe3O4) Automotor, cosmetic, electronic and medical products, refrigerators and air humidifi‐
ers
TiO2 Electronic devices, cosmetic industry, water and cleaning products, solar cell industry,
antimicrobial and disinfectant sprays
Gold (Au NP) Medical products, electronic industry, fuel and lubricants, food and beverages,
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Solar cells, electronics, semiconductors and dye and medical uses
ZnO Cosmetics, paints and varnish, packaging and personal care products, paints, cleaning
products, sprays




Grinding tools, automotor, polishing, electronic, plastic, dyes industries
Nanoclays Cosmetics and personal care, packaging, water managements, flame retardants, paints
Ceramics Paints, personal care products, filtration systems, coatings
Cerium oxide (CeO2) Coatings, paints, automotor and fuel cell industry
Carbon NPs: C60, C70, Nano‐
tubes, Carbon Black, Gra‐
phene NPs
Electronic devices, catalysts industries, water managements and filtrations, sensors,
automotor and sports, clothing and packing, sensors, plastics, cosmetics, refrigerators
and air humidifiers
There are countless challenges and issues when it comes to assessing unintentional exposure to NPs. The huge
variations of the same chemical structure of NPs, i.e. different sizes, shapes, different functionalization, and impuri‐
ties, manifest a massive burden to evaluate the safety of each NP on a single basis. Knowledge gaps still exist regard‐
ing NP behavior in the environment from their release site to their deposition into an organism; their interactions with
other ecological elements; their biodegradation or bioaccumulation; the amount or the internal dose that can be de‐
posited in an organism; and to what extent by which route of exposure the dose accrues. This knowledge will help to
determine if their environmental concentration is decreasing or increasing over time, set the measures to control it,
identify the post-exposure ecological and biological effects, and determine if the interaction will render them less or
more toxic (Kuhlbusch, Wijnhoven, and Haase 2018). The literature has many studies presenting the increased risk of
pulmonary diseases, and other cardiovascular problems, in those living in very air-polluted cities and near motor‐
ways, and relating these problems to diesel exhaust particles, fibers, fire ashes and soot, as well as their constituent
particle types: coarse, fine, and ultrafine particles. More studies are needed to uncover the toxicity of the ultrafine
particle fraction. The major difficulties in the real-time assessment of exposure at the environmental setting are due to
the lack of adequate technologies that can count the particles, assess their size fractions, and determine their nature
and probable sources from direct air sampling (Nowack 2017). Most of the current sampling is achieved either at the
site of release of these particles, for example, from industrial drainage, or at the site of settling of these particles, for
example samples from soil or water that are miles away from the production site. Many technological hurdles are still
to be overcome to assess the environmental journey of NPs either from natural or anthropogenic sources to build real‐
istic quantitative exposure risk assessments and firm conclusions (Nowack 2017; Jantunen et al. 2018).
The assessment of NPs exposure at the occupational settings is still developing to address the emission of NPs, set
measures to control their release into the environment and to develop the protective equipment for the workers. Many
studies have suggested the relationship between the releases of particulate matter at the workplace and long-term hu‐
man diseases. One of the earliest studies draws attention to workplace exposure to NPs where seven women devel‐
oped serious lung issues after long-term occupational exposure to NPs and MPs of polyacrylate, silica, and silicates.
These particles were found in their tissue samples and Bronchoalveolar lavage (BAL) but no firm conclusion of cau‐
sation against the NP fractions was found (Kuhlbusch, Wijnhoven, and Haase 2018; Forest et al. 2019). Asbestosis
and silicosis are well-known lung pathologies caused by occupational exposure to inhaled dust and particles of biore‐
sistant materials as asbestos, silica, and other minerals. There are well-established measures to do air monitoring dur‐
ing the occupational setting but these still lack the assessment of the ultrafine fractions that probably have more reac‐
tive and larger surface areas, as well as larger numbers of these particles. Air monitoring has overlooked considera‐
tion of an individual’s susceptibility (i.e. any concurrent breathing problems, breathing patterns, or genetic or general
predisposition), or their relative personal exposure (i.e. how long the exposure, frequency of that exposure, what par‐
ticles, pure or mixed with impurities, soluble or bioresistant, their physicochemical properties) (Abdolahpur Monikh
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et al. 2018). The calls for co-implementing bio-monitoring is urgently needed where measuring the internal dose can
reflect the deposited dose and assess the individual clinical picture. Some research studies are proposing approaches
of monitoring the load of NPs in patients’ samples and their clinical conditions and propose extracting these particles
to be used for in vitro experiments to assess their toxicity; what is called in vivo to in vitro testing (Forest et al. 2019).
Other studies call for assessing different particles collected from different environmental or occupational settings and
then studying their safety. This creates unrealistic economical, technical, ethical and time-scale burdens to achieve,
hence the calls for grouping NPs to allow for read-across of their safety and the urgent need to enhance the reliability
and relevance of the in vitro testing, abiotic functional assays, and in silico models (Abdolahpur Monikh et al. 2018;
Basei et al. 2019; Lamon et al. 2019).
With the increasing number of products that contain NPs (either embedded in a solid matrix where aerosolization
is very rarely expected, or in a suspended form where aerosolization can occur), much less is known about how NPs
can be released into the environment, and other associated ecological and biological effects. Most of the consumer
exposures, for example, spray products containing NPS, are based on modeling methods that measure the exposure
on simulated environments but still suffer from the same issues of the occupational exposure, i.e. neglecting the fre‐
quency of the exposure, the individual susceptibility, and the different NPs interactions prior to deposition that might
aggravate the harmful effects (Nowack 2017, Steinhäuser and Sayre 2017, Kuhlbusch, Wijnhoven, and Haase 2018,
Basei et al. 2019). More studies are urgently needed to study the release of NPs from occupational settings and con‐
sumer products into the environment, and to assess the short-term and long-term exposure risks. When this knowl‐
edge is available, this will help set accurate quantitative risk-exposure estimates and set regulatory measures to pro‐
tect humans and the environment when handling, using, and disposing of NP-containing materials.
4. Nanotoxicology and the regulatory bodies of nano applications
Nanotoxicology was enabled in 2004 as a new category of the classical toxicology to address the challenges with
NPs assessments (Donaldson et al. 2004). It focuses on uncovering the mechanistic relationship between NPs physi‐
cochemical characteristics and the consequential biological effect. Moreover, it scopes optimizing the experimental
conditions for in vitro and in vivo evaluation to detect possible NPs interference with different assays, and to provide
the safety assessment data for this nanomaterial, and their applications (Joris et al. 2013). The novelty and complexity
of NPs and their biological responses had raised issues regarding; which is the critical parameter in their toxicity, i.e.
what is the NP dose mass, number, physical or chemical characteristic, route-dependent toxicity or a combination of
all (Buzea, Pacheco, and Robbie 2007). The Dearth of standardized assays and pre-set regulations have made it diffi‐
cult to compare the available literature regarding their safety. Over two decades, the scientific community has under‐
gone extensive debates and yet failed to come to a common ground about the NPs metrics, definitions, classifications,
characterizations, safety/toxicity characteristics, toxicity endpoints, target endpoints, occupational/environmental ex‐
posure limits, and standardized assessment methods. Many government and non-government bodies are working
closely to address the regulatory challenges with efforts to bridge the international harmonization and standardiza‐
tions. For example, nano-based products for consumer use are mostly under regulation by many organizations within
USA; as USNCL, FDA and EPA. These organizations have a set of protocols to evaluate the safety of these products
prior to their marketing, starting from benchtop development, manufacturing, occupational, environmental, and bio‐
logical risk assessments and clinical trials. Similarly, in Europe, organizations such as EUNCL, EMA, and others are
providing standards and protocols to regulate nano-based products. They provide a set of protocols to assess the safe‐
ty of nanomedicines (Sainz et al. 2015; Accomasso, Cristallini, and Giachino 2018; Siegrist et al. 2018). In the UK,
organizations like DEFRA, FSA, DH, ISO, OECD, REACH are controlling the handling, use, and assessment of
nanomaterials (Rasmussen et al. 2019). Detailed and recommended methods for physicochemical characterizations of
NPs, for occupational, environmental, and consumer exposure modeling; and for in vitro/in vivo methods of nanotox‐
icological testing, agreed by a variety of regulatory bodies to assess different nanomaterials, can be found in these
sources (Sainz et al. 2015; Drasler et al. 2017; Nowack 2017; Steinhäuser and Sayre 2017; Abdolahpur Monikh et al.
2018; Kuhlbusch, Wijnhoven, and Haase 2018; Lamon et al. 2019).
4.1. Inhaled nanoparticle ADME kinetics and toxicity
Upon pulmonary administration of NPs aerosols, the smaller the size of the NP aerosol, the deeper they can travel
into the lung. Once deposited, NPs interact with a group of biological and cellular barriers starting from the surfactant
layer, mucus, epithelial cells, vascular endothelium, and interacting with different molecular and cellular structures in
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the biological environments prior to exerting a drug response (Figure 2). NPs have to be absorbed and transported
into their targets faster than the rate of their clearance and degradation. NPs will be up taken by the alveolar epitheli‐
um where they can be transported through the paracytosis or transcytosis pathways (Forest, Vergnon, and Pourchez
2017). Locally delivered NPs, results in prolonged lung retention, which is aimed to achieve site-targeting, increase
the duration of action, lower the dosing frequency, and minimal off-target side effects. On the other hand, the longer
lung retention might cause local NPs toxicity, and the possibility of NPs escape through the thin alveolar epithelium
to systemic circulation producing off-target side effects (Bourquin et al. 2018). For example, in an in vivo study in‐
volving female Wistar strain WU rat, Ag NPs of 50 nm size and coated with polyvinyl pyrrolidine (PVP) (previously
tested in vitro against alveolar macrophages and were more cytotoxic as determined by LDH release than NPs of
200 nm) were administered via intratracheal instillation in a single exposure of a dose from 0, 37.5, 75, 150, 300, 600
(w/v) µg per rat lung as a shot of 500 µl isotonic saline solution, and compared to600 µg dose of Ag NP-200 nm. At
day 3 and 21 days post-exposure, BALF was collected, with histological evaluation of the lung tissues, liver, kidneys,
RES (spleen, and lymph nodes) for subsequent Ag quantification and imaging by ICP-MS and microscopy. Ag NP 50
and 200 nm at 600 µg were associated with severe pulmonary inflammation with dead cells, ruptured macrophages,
and detached epithelial cells denoting the high toxicity of the Ag NPs, so the dose was limited to 300 µg. The 200 nm
size showed more prominent inflammatory signs than the 50 nm and the study was continued with the 50 nm NPs.
The BALF was evaluated for the high level of cytokines and other inflammatory mediators, where Ag NP-50 nm
doses from 75–150 µg showed a reversible inflammation, 300 µg had caused progressive inflammation with infiltrat‐
ing neutrophils, cell proliferation and DNA damage with single and double-strand damage. Significant accumulation
of Ag NPs in the distant RES organs was associated with doses above 75 µg, with focal pools of Ag NP partly attrib‐
uted to the wondering macrophages, other localizations were found in the kidney proximal tubules, denoting the abili‐
ty of the NPs to be retained locally and migrate systematically causing target and off-target side effects. A drawback
in this study, is the lack of Ag NPs quantification of the lung tissue load (Wiemann et al. 2017).
Figure 2. Pharmacokinetic of inhaled NPs and their potential toxicity.
Systemic NPs delivery via inhalation, NPs traverse the whole respiratory membrane to the blood where they will
be carried and delivered to the systemic targets. NP systemic translocation was reported to be size dependent process
but no solid threshold is clear, for example, it is ten times higher for NPs of 20 nm than 80 nm Iridium, or forty times
higher for 1.4 nm than 18 nm Au NPs (Rinaldo et al. 2015). NPs can be retained at the site of action by EPR effect as
in case of tumors or been actively targeted by certain antibodies to migrate to certain types of cells. Some NPs travel
through the olfactory epithelium to the brain (Samaridou and Alonso 2018).
NP metabolism and clearance have shown many variations. With the use of lung delivery for both systemic and
local delivery, the low metabolizing activity will increase the pulmonary retention of NPs and prolong their action
(Olsson et al. 2011). This could be advantageous, where the lung acts as a stable reservoir of the NPs for sustained
delivery and clearance. Up till now, the full lung metabolizing capacity is not fully recognized with little information
known about any enzyme induction or inhibition apart from smoking; a well-known lung metabolizing inducer
(Kroon 2007), the lung enzymatic inhibition could increase the potential clinical side effects and toxicity of locally
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delivered NPs (Olsson et al. 2011). Particle elimination and NPs elimination from the lung can be attributed to their
dissolution/solubility in the interstitial fluid or physically eliminated by mucociliary or macrophages clearance (Ri‐
naldo et al. 2015).
The biodegradable NPs products will eventually be cleared by the renal system. The renal clearance is limited to
NP or NP products size lower than 8 nm (Longmire, Choyke, and Kobayashi 2008). The physical clearance of NPs
could be achieved either with the fast mucociliary in the conducting zone, or the slow macrophages clearances in the
respiratory zone. The NPs swallowed into the stomach, might undergo fecal clearance or reabsorption to the systemic
circulation. Furthermore, the macrophages might entrap these NPs resulting in an inflammatory reaction upon ex‐
ceeding the macrophages ability to digest. Macrophages have less-efficient clearing for NPs with a size below 70 nm,
moreso, rod or fiber-like NP are very challenging for phagocytosis resulting in frustrated macrophages (Bakand and
Hayes 2016). NPs can be drained to the local lymphatics and lymph nodes either delivered by loaded macrophages or
sole NPs drainage to lymphatics. From lymphatics, NPs can travel to the systemic circulations and end up in the retic‐
uloendothelial system (RES) (liver, spleen, bone, and others) where further chemical digestion or physical retention
will occur causing off-target side effects. It is unknown, how much of the inhaled NPs is retained in the lungs or
escape to the systemic circulation, or the duration within the lung retention (Zhao et al. 2019). Although the enhanced
properties of NPs stem from their nanosize and their physicochemical properties but it still requires optimization of
the NP and its formulation to suit the planned route of entry as evidenced in many studies (Donahue, Acar, and Wil‐
helm 2019). Kreyling et al. had published a series of NPs administration studies via intratracheal instillation, oral, and
IV injection for the same type of NP in rats where differences in the bioavailability, distribution, clearance and elimi‐
nation were noticed from 1 hr up to 28 days (Kreyling, Holzwarth, Haberl, Kozempel, Hirn, et al. 2017; Kreyling,
Holzwarth, Haberl, Kozempel, Wenk, et al. 2017; Kreyling, Holzwarth, Schleh, et al. 2017) indicating the unsuitabili‐
ty of adopting the kinetics for NPs from one route to be applied to another route of administration. Another study had
shown the lung retention of gadolinium NPs administered as contrast agent was much better and tumor-limited with
no lung inflammation induced by local lung delivery compared with the same particles injected through IV route in‐
dicating targeting the lung by local delivery shows superior results from systemic lung-targeting (Bianchi et al. 2014;
Dufort et al. 2015). In vivo animal study in Sprague-Dawley male rats were exposed to TiO2 NPs anatase ∼20 nm,
15 mg/m3 during 6 hrs inhalation using nose-only inhalation chambers. Rats were euthanized at 0, 3, 6, 12, 24, 48,
72 hrs, 7 and 14 days. Quantification of the NPs retention by ICP-MS in the lungs, blood, heart, brain and olfactory
tissues, lymphatic, liver, pancreas, salivary glands, spleen, lymph nodes, thymus, feces and urine were done at the
time intervals. Lung slices were collected for TEM analysis after 6 hrs exposure. Oxidative damage were detected by
the malondialdehyde (MDA; marker for lipid peroxidation) using thiobarbituric acid reacting substances (TBARS)
assay from the blood levels and tissue levels at 1, 3, 7 and 14 days intervals. In the Lungs, the max peak NPs load
was achieved 48 hrs after the exposure, with a slow progressive decrease over 14 days, denoting that the NPs were
retained/impacted with slow translocation to the lung tissues. In the blood, the max peak was 12 hrs post-exposure
and high levels were detected in lymph nodes and other internal organs, denoting the systemic translocation. The total
amount translocated to blood and lymphatic was low compared to the retained amount on the lungs. MDA was signif‐
icantly high in the lungs, blood and main tissues (liver, spleen, kidneys) 24 hrs after exposure with fast decline over
14 days. Feces and urine contained large amounts of the eliminated NPs and this can be explained by the mucociliray
clearance to the GIT, liver drainage, blood translocation to the kidneys. Olfactory bulb and brain contained high lev‐
els of NPs but there was no firm conclusion if the NPs had been translocated through the olfactory bulb and nerves to
the brain, or simply was directed from the systemic circulation. From this study, it was concluded that lung transloca‐
tion to the blood was the main source for NPs available for the systemic distribution. Highest levels of NPs were in
lungs followed by liver and then kidneys during max peaks and over 14 days. Feces primarily and urine secondarily
were main elimination routes for the NPs denoting the effectiveness of mucociliary clearance (Pujalte et al. 2017).
Another animal study demonstrated the systemic distribution and accumulation after inhaling Gold NPs and off-target
initiating inflammation (De Matteis 2017).
The NP kinetic variations from one route of administration to another, i.e. inhalation versus parenteral and oral
routes. The NPs physicochemical and formulation properties designed to suit a specific route, are not going to be
suitable for another route because of the differences in biological barriers at the site of entry with differences in the
structural, physiologic and chemical environments. Another strong factor is the protein corona, upon contact of NPs
with the fluid environment of the barrier site, a layer of proteins and other molecules of that fluid medium will wrap
the NPs giving what is called a new identity for the NPs that plays in the safety and efficacy of the treatment (Moore
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et al. 2015). This may lead to NPs aggregates and more prone to phagocytic uptake, or the physicochemical proper‐
ties may change implicating changes in their kinetic behavior either limiting their effect or intensifying their toxicity
(Bello and Warheit 2017). Further details about the protein corona and its effects on NP activity can be found in these
sources (Monopoli et al. 2011; Vilanova et al. 2016; Ânia et al. 2018; Nierenberg, Khaled, and Flores 2018; Cao et al.
2019). A stealth/shielding technique for NPs are currently designed to limit the effect of protein corona (Vij et al.
2010). Therefore, a single NPs safety scenario concluded by one route might not guarantee the safety for another
route of administration. This means each route of entry must be tested separately. A nanotoxicological evaluation on
a single NP case should be assessed covering the nanocarrier physicochemical properties, nanocarrier-drug formula‐
tion factors, with in vitro/in vivo evaluation prior to clinical trials. Recently applying in silico models after in vitro
studies was successful to predict the in vivo kinetics of gold aerosolized NPs (Bachler et al. 2015; Donahue, Acar,
and Wilhelm 2019). A growing concern which is not yet much explored is the ability of NPs to cross the placental
barrier and causing developmental fetal problems.
4.2. Nanoparticle interaction at cellular and molecular levels
NPs ability to overcome the biological barrier and interact with the cell is a physicochemical-dependent process.
Each NP delivery system should be characterized and studied on a single case scenario. The aim of NPs as drug de‐
livery carriers is to deliver the cargo to certain cells, or more specifically, to certain subcellular locations, to exert a
response. Cellular uptake can be mediated by various mechanisms; passive or carrier-mediated or endocytosis. For
NP-mediated drug delivery, nanocarriers are of high molecular weight and mostly subjected to vesicular transport or
endocytosis (Wang et al. 2012; Jameson et al. 2019). Endocytosis pathways involve many processes; pinocytosis pro‐
cesses and phagocytosis. Pinocytosis is the cellular uptake of small-sized particles and fluids and includes micropino‐
cytosis, clathrin-, and caveolin-dependant and independent mechanisms (Figure 3). While the phagocytosis is the up‐
take of larger debris, particles, and bacteria and is only carried by professional immune cells such as macrophages
and neutrophils. Further details of these different mechanisms can be reviewed in these sources (Aderem and Under‐
hill 1999; Conner and Schmid 2003; Elkin, Lakoduk, and Schmid 2016; Donahue, Acar, and Wilhelm 2019; Jameson
et al. 2019). NP uptake mechanisms are physicochemical dependent processes and cell-type dependent. Post uptake
NPs vesicles will be fused with the early endosome (EE) where a low pH digestive activity can take place degrading
the NPs. The lysosomal digestion carries many potentials of intracellular and targeting delivery of pH-sensitive NPs.
This is of benefit in the case of tumors where their extracellular environment has low pH (Dominska and Dykxhoorn
2010). Lysosomal/endosomal escape is a challenge for the subcellular NP targeting to cell organelles (Li, Cheng,
et al. 2014), i.e. nucleus (Li et al. 2017, Pan, Liu, and Shi 2018) and mitochondria (Salnikov et al. 2007; Chen et al.
2016; Eftekhari 2018). Endosomes have complex machinery that allows for NP vesicular sorting, digestion and deg‐
radation, and waste-exocytosis and recycling as well as initiating cellular death in case of toxic NP overload. Full
endosomal maturation cycle and their role in NP degradation can be reviewed in these sources (Scott, Vacca, and
Gruenberg 2014; Elkin, Lakoduk, and Schmid 2016; Rothen-Rutishauser, Bourquin, and Petri-Fink 2019). Some NPs
can be found without vesicles in the cytoplasm (Bourquin et al. 2018). NPs may translocate to cytoplasm, mitochon‐
dria, nucleus or other cellular organelles and molecules, and may evoke a cytotoxic response (Jiang et al. 2010; Shi
et al. 2011; Donahue, Acar, and Wilhelm 2019).
Figure 3. Main uptake mechanism of NPs and the endocytic pathways. EE: Early Endosome-low pH; LE: Late endosome-low pH;
ER: Endoplasmic reticulum; L: Lysosome-very acidic; N: Nucleus; M: Mitochondria; G: Golgi; RE: Recycle endosome.
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4.3. Proposed mechanisms of NPs toxicity
NP toxicity is still one of the hot topic areas due to the novelty of their materials that render the NP with unique
physicochemical properties. These exceptional properties are not only tremendously critical for their efficacy but also
for their toxicity with partly or complete dose-independent. Cellular injury might vary from trivial reversible injuries
recovered by the efficient cellular repair mechanisms to severe or irreversible injuries inducing cell death or long
term adverse effects (Donahue, Acar, and Wilhelm 2019). Various intersecting toxic mechanisms were reported upon
exposure to various types of NPs, or even to the same chemical structure NP with variable physiochemical properties
(Figure 4). Up till now, there is no agreed solid background as to which is the single and the most critical parameter
for NP toxicity, for example, is it the size only, or the chemical composition, or the mass? Unlike the same bulk coun‐
terparts, the mass dose is not such critical for the toxicity (apart from being overtly overdosed that would generate
toxicity anyway) and the full identity of physicochemical properties of the NPs is critical. As a result, a full thorough
NP characterization is a must prior to their testing and drawing conclusions. In this literature review, the authors fo‐
cused on NPs toxicity that was based on different types of NPs, such as organic NPs, i.e. polymeric natural or syn‐
thetic that are commonly used for drug delivery to the lungs, carbon-based such as CNTs and carbon black that are
common in environmental and occupational setting inhalation, and metallic NPs such as Ag, Au, Zn, Silica, TiO2
NPs that have more risks of occupational and consumers risk from inhalation. Although most of the in vitro research
pool is based on lung cell lines exposure to suspended NPs and that is due to the expensive nature and the extreme
difficulty to achieve aerosolization exposure to in vitro cell lines. The value of the initial in vitro step is establishing
the relationship between the NP physicochemical identity to biological or toxicological responses, uncovering the un‐
derlying mechanisms, a possible high throughput screening, developing in silico predictive modeling, and reducing
the animal load (Xia et al. 2016). The in vivo based experiments are inhalation exposure but with varied routes of
delivery, i.e. oral- or nasal-delivery, whole body exposure, intratracheal instillation or cannulation. These studies will
provide solid frameworks to understand the toxicity of NPs aerosols on the lung due to the novelty of the aerosolized
NPs.
Figure 4. NP cellular uptake and interactions with different mechanisms of cytotoxicity.
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4.3.1. Cell membrane disruption
Membrane disruption due to NPs interactions could be mediated via various mechanisms (Donahue, Acar, and
Wilhelm 2019; Farnoud and Nazemidashtarjandi 2019). Positively-charged NPs interact with the negatively charged
cell membrane altering, depolarizing or damaging the membrane i.e. thinning, pore formations and erosions (Yeh
et al. 2013; Jameson et al. 2019). The negative charge NPs could also affect the membrane potential through the elec‐
trostatic interactions with the lipids causing lipid leakage (Mu et al. 2014). Surface chemistry is another important
factor, where a lipid-bilayer damage and RBCs hemolysis was attributed to the presence of surface Silanol groups
with amorphous silica NP and not with mesoporous Silica NPs (Slowing et al. 2009). ROS production and subse‐
quent lipid peroxidation is another membrane damaging mechanism where it could be prevented by the use of anti-
oxidants (Sayes et al. 2005). Inhibition or stimulation of the membrane ion channels upon NPs interaction with subse‐
quent loss of control over the cellular ionic pool can lead to membrane damage. Membrane depolarization and loss of
control of Ca2+ influx with further proliferation inhibition were dependants on surface charge, with positive NPs hav‐
ing an influence in both malignant and nonmalignant human cells (Arvizo et al. 2010). Blocking of K+ channels is
another example of membrane induced damage (Chhowalla et al. 2005), for example, impurities of yttrium within
Carbon NPs were found to inhibit the K+ channels (Jakubek et al. 2009). Cytoskeleton alteration is another mecha‐
nism where NPs can functionally block the F-actin and α- or β-tubulins, which are the major functional proteins. This
cytoskeleton plays an important role in preserving the cellular shape, motility, adhesion, transport, and cellular divi‐
sion and proliferation. PEGylated NPs were found to reduce this cytoskeleton affect (Tarantola et al. 2009). Polystyr‐
ene NPs showed inverse correlation between the size and the membrane interaction in vitro cell membrane model
(Peetla, Stine, and Labhasetwar 2009; Accomasso et al. 2016). Fiber SWCNT NPs showed an increase in the ROS
production due to physical needle-like effect disrupting the cell membrane and other subcellular structures, for exam‐
ple entangling the internal actin cytoskeleton, centrosome structures, nucleus, and DNA (Saifi, Khan, and Godugu
2018).
4.3.2. Oxidative stress
When ROS production exceeds the cellular ability to inhibit, this induces what is called oxidative stress where free
radicals will react with the cellular components, proteins, membranes inducing cellular dysfunction, inflammation,
lipid peroxidation, mitochondrial shutdown, molecular and DNA damage, and eventually cell death, either through
the apoptosis if its less severe insult or through necrosis with severe toxic insults (Mu et al. 2014, Donahue, Acar, and
Wilhelm 2019, Evans et al. 2019). Furthermore, almost all types of NPs had shown toxicity that is linked to the pro‐
duction of ROS and this could be determined by measuring free radicals and GSH levels (Anttila et al. 1997). NPs
ability to induce the ROS is dependent on its physicochemical properties. The metallic NPs enhance the ROS produc‐
tion by catalyzing reactions like Fenton’s or Heiber-Weiss with free radicals production. Park et al. showed the reduc‐
tion of ROS production after addition of antioxidant N-acetylcysteine with Ag NPs (Saifi, Khan, and Godugu 2018).
ZnO NPs triggered cytotoxicity in primary pulmonary cell line BEAS-2B, via ROS, Ca2+ spill, mitochondrial mem‐
brane disruption that was observed as well in A549 cells (Shin, Song, and Um 2015). ZnO NPs were associated with
ROS and acute inflammation in vivo lung study and was claimed to be due to the NPs dissolution or its ability to shed
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Zn ions that induced the oxidative stress and inflammation. Carbon NPs such as carbon black NPs or CNTs were able 
to induce ROS in in vitro cell-free media and to cultured cells. Organic compound redox-cycling reactions are respon‐
sible for production of free radical anionic compounds such as polycyclic aromatic hydrocarbons (PAHs). ROS could 
be due direct insult to the mitochondrial membranes or processes with inability to energize the cell (Xia et al. 2016).
4.3.3. Cell organelles damage and mitochondrial shutdown
NPs ability to interact with the cellular components and induce membrane damage and ROS will suggest potential 
toxicity on the mitochondria. Direct NP-mitochondrial interaction was noticed causing lipid membrane damage and 
leakage in which 3 nm gold NPs were localized into the mitochondrial membranes causing its dysfunction and leak‐
age (Salnikov et al. 2007). Lysosomal damage either by chemical sponge theory or physical needle like shaped NPs
rupturing the lysosome and releasing Ca2+ from the endoplasmic reticulum with eventual loss of control of mitochon‐
drial permeability. In addition, lysosomal rupture and enzymatic spillage might activate apoptosis pathways and other 
carbon-based and fullerenes are reported to cause mitochondrial damage. The mitochondrial damage with loss of en‐
ergy production and antioxidant properties will results in high ROS, nuclear and DNA damage, and membrane dis‐
ruption (Saifi, Khan, and Godugu 2018, Donahue, Acar, and Wilhelm 2019).
4.3.4. DNA damage and mutagenicity
This could be direct NP genotoxic effect or indirect effect through the induction of inflammation, inflammatory 
mediators or ROS, molecular and organelle damage (Doak and Dusinska 2017[Singh et al. 2017). Due to the high 
surface energy of the NPs, DNA as any other biological molecule is subjected to surface adsorption. This bind‐ing 
will induce both conformational and functional deformity of these biomolecules. Carbon based NPs were found to 
induce DNA-double stranded to cleave under light or with the presence of copper ions (Mu et al. 2014). Gold NPs 
were found to induce conformational changes as relaxation of the DNA strand coils, cleavage of the double strands 
(Railsback et al. 2012) and functional changes as inhibition of the transcription (Mcintosh et al. 2001). TiO2 NPs 
caused oxidative stress and production of free radicals that resulted in subsequent DNA damage (Donaldson, Bes‐
wick, and Gilmour 1996). TiO2 NPs showed DNA damage by causing breaks and other oxidative DNA dysfunction 
with impairing the repair mechanisms (Saifi, Khan, and Godugu 2018). Cationic PLL coated silica NPs were found to 
cause DNA transcription inhibition that was size dependent (strong irreversible DNA adsorption with size 40 nm NPs 
that was reversible with the smaller size 10 nm NPs) (Zinchenko, Luckel, and Yoshikawa 2007). Long-term studies 
are required to investigate NPs-genotoxicity with the development of cancer. Some QDs NPs were reported to cause 
DNA fragmentation (Mu et al. 2014).
4.3.5. Inflammation
Upon macrophage recognition and phagocytosis, inflammatory mediators are released which initiates an inflam‐
matory response. This is a physio-pathological reaction which in excess or persistence of inflammation could predis‐
pose to autoimmune disease, long term diseases, and cancer (Donahue, Acar, and Wilhelm 2019). For the lung, the 
inflammatory potential of NPs designed for drug delivery should be excluded. The size (below or larger than the al‐
veolar macrophages) will bypass the macrophages recognition and phagocytosis. NPs agglomerates are another prob‐
lem during drug delivery of NPs to the lungs, as they increase the size of the particle favoring their impaction away 
for the alveoli or favoring their clearance. When the macrophages clearance is overwhelmed by NP size, shape, 
chemistry, particle number and agglomerates or surface group with prolonged pulmonary retention due to slow or 
incomplete degradation and metabolism, inflammatory response will be evoked. Due to their nanosize, NPs showed 
longer retention time and less efficient lung clearance in in vivo inhalation study (Bakand, Hayes, and Dechsakul‐
thorn 2012). It has been known from the pathogenesis of lung silicosis that long fibers were trapped longer due to 
defective clearance with subsequent inflammatory induction. Another in vivo study showed the lungs had overburden 
and prolonged retention of long fibers (4-12 nm) TiO2 NPs compared with the spherical NPs (Porter et al. 2013). 
ZnO NPs of 50 nm size were investigated against air-blood barrier of co-cultured continuous lung NCI-H441 and the 
vascular HPMEC-ST16R in transwells, where increased levels of the proinflammatory mediators, IL-6 and IL-8, 
were detected (Shin, Song, and Um 2015; De Matteis 2017). Hence, multiple parameters of NPs physicochemical 
characteristics play a role in inflammation induction (Braakhuis et al. 2014). Furthermore, Amorphous silica NPs in‐
duced inflammation and cell death with generation of ROS (Fu et al. 2014).
A new potential mechanism involved in the inflammation cascade is the NLRP3 inflammasome activation with 
rising IL-1β. Certain pathogens, toxins or particles might induce this mechanism with a rise of the IL-1β through acti‐
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vation of caspase 1 and initiation of inflammatory induced apoptosis or known as pyroptosis. Several studies have
shown NPs can induce the NLRP3 activation, for example, some liposomes and polymer-based NPs. This is benefi‐
cial in case of vaccines delivery. A detailed source for this mechanism and its assessment can be found in these fol‐
lowing sources (Sharma et al. 2018; Shirasuna, Karasawa, and Takahashi 2019).
4.4. Cell death mechanisms
Cell death is the final fate after any irreversible cytotoxic or stress insult and can be either programed cell death
known as apoptosis, or unprogramed cell death known as necrosis. Very recently, the Nomenclature Committee on
Cell Death had adopted new considerations to replace the old cell death classification to the new adopted and emerg‐
ing mechanisms proved by many studies that have discovered variable mechanisms of the programed cell death such
as apoptosis, autophagy, ferroptosis, pyroptosis, necroptosis, paraptosis, lysosomal-induced, autoimmune-induced,
and many others. These processes have different fundamental mechanisms with different underlying biological and
histological picture of the cell death (Mohammadinejad et al. 2019; Tang et al. 2019). The uncontrolled cell death
(known as necrosis) is commonly a passive accidental cell death due to energy failure or simply bursting in response
to severe acute insult. Detailed information for these mechanisms is found in these sources (Rothen-Rutishauser,
Bourquin, and Petri-Fink 2019; Tang et al. 2019). NPs can induce complex death mechanism with many intersecting
activation of different death pathways with a physicochemical dependent manner (Mohammadinejad et al. 2019).
NPs can trigger many intrinsic and extrinsic pathways and induce apoptosis, autophagy, lysosomal-induced cell
death, for example, in some metallic NPs such Nickel oxides, silicon dioxide, TiO2, and SWCNTS. These NPs-in‐
duced cell death mechanisms involve caspases activation, ROS production, mitochondrial shutdown, lysosomal dam‐
age (De Stefano, Carnuccio, and Maiuri 2012). Although some inconsistencies are found in the literature regarding
the necrosis where some researchers considered the loss of cell or the decreased viability as necrosis. There are many
studies that claim different cytotoxicity’s with different cell death mechanisms after exposure to TiO2 NPs but lack
the specifications of NPs crystal structure. TiO2 with different nanosizes and crystal structure (rutile and anatase) had
induced cell death; anatase TiO2 NPs induced necrosis whereas the rutile TiO2 NPs induced apoptosis and was con‐
centration dependent.
4.5. NPs physicochemical-dependant toxicity determinants
4.5.1. Nanoparticle size, surface area, and aspect ratio
NPs have intrinsic properties that play a role in their beneficial advantages as well as their toxicity (Figure 5 and
Table 5). Due to their nano-size range, they have large surface area-to-volume ratio, which explains their high reac‐
tivity and strong adsorption properties. Moreover, the high surface energy tends to facilitate the NP-cellular or biomo‐
lecular interaction, and NP-NP interactions. This cellular interaction might be in a beneficial way. On the contrary, it
may increase the production of ROS and/or RNS. This is due to high surface area catalysis (Liu et al. 2010). Oberdör‐
ster et al demonstrated in pulmonary in vivo study that smaller size NPs showed more persistent lung inflammation
with prolonged pulmonary retention and interstitial translocation, and impaired macrophage clearance than larger size
NP of the same crystal structure (Oberdorster, Ferin, and Lehnert 1994). NPs with size 1.4 nm showed more cytotox‐
icity than 15 nm size of the same NP structure by inducing more ROS and mitochondrial damage (Pan et al. 2009).
Carbon black NPs with larger surface area (270 m2/g) had more cytotoxicity on rat lungs than larger particles with
smaller surface area (22 m2/g) (Nikula et al. 1995; Driscoll et al. 1996). Silica NPs with size of 1.2 and 22 nm
showed passive transport compared with the larger NPs (greater than 22 nm) that transported through membranous
vesicles in in vitro study (Roiter et al. 2009). A size range of Ag NPs was assessed after inhalation in rats, NPs with
the smaller size (18, 34 nm) showed higher cytotoxicity than larger NPs (60, 160 nm) after 24 hrs exposure. The
cytotoxicity was measured by the amount of leaked LDH that showed to be size and surface area-dependent rather
than dose-dependent damage (Braakhuis et al. 2016). The size of NPs is suitable for many uptake and endocytosis
mechanisms with larger particles around 100 nm or more are endocytosed via clathrin-mediated while the size below
80 nm is mediated by caveolae-dependent mechanism. However, there are many examples of larger or smaller NPs
uptaken by various endocytic mechanisms (Shin, Song, and Um 2015).
Figure. 5. Nanoparticle physiochemical properties.
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CNTS are considered to have a high aspect ratio, which means that one of the NP dimension is very long, i.e. fiber
or rod shaped structure. CNTS have many applications in both industrial and pharmaceutical drug delivery applica‐
tions. CNTS have shown the pro-fibrogenic properties with NLRP3 activation with IL-1β, TGF-β and growth factors
PDGF-AA involved in inflammation, fibrosis, and cell death. Other high aspect ratios of NPs were investigated in
vitro, such as CeO2 NPs (with >200 nm length and aspect ratio >22 nm), showed more inflammation and cytotoxicity
compared to the spherical shaped (Xia et al. 2016). Small aspect ratio 6-10 nm showed cell membrane perforation
and organelle damage and leakage of lysosomal contents with the stack bundle or needle shaped perforation (Lin
et al. 2014).
4.5.2. Nanoparticle surface properties
NPs with a specific charge, surface coatings or modifications are intentionally designed to achieve some pharma‐
ceutical or therapeutic targets such as increasing the stability of the formulation, increasing the efficiency of protein
adsorption with cationic NPs, reducing the immune system recognition, prolonging the circulatory half-life (Mu et al.
2014). This surface charge is measured by determining their Zeta potential. The surface charge is designed using dif‐
ferent surface coatings or modifications, i.e. positively charged NP (coated with amine groups such as 1,2-Dioleo‐
yl-3-trimethylammoniumpropane (DOTAP), chitosan), or negatively charged NP (coated with acidic groups such as
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Polyvinyl alcohol (PVA), poloxamer188 (PF68) or neutral NP charge (near the neutral or slightly negative charged
NPs) (Mura et al. 2011). The NP charge plays a major determinant role for their cellular uptake and interactions. Pos‐
itively charged NPs exert higher cellular uptake, internalization and biomolecular interactions more than negatively
and neutrally charged NP and subsequently a higher cytotoxic effect (Bhattacharjee et al. 2010). Their cytotoxicity
has been associated due to membrane depolarization, ROS production or mitochondrial damage (Schaeublin et al.
2011). Quartz NPs with surface negatively charged coating showed less particle uptake and inhibition of the oxidative
DNA damage in A549 cells compared with the non-coated quartz NPs (Schins et al. 2002). Negatively charged lipo‐
somes showed longer blood circulation in comparison to the neutral NP, with the positively charged showed faster
clearance and higher toxicity (Bourquin et al. 2018). Similarly, positive charged polymeric dendrimers PAMAM/G4
showed more toxicity compared to the anionic NPs on zebrafish and mouse embryos (Gatoo et al. 2014). Another
study had shown the effect of surface coating and the resultant charge; liposomes loaded with elcatonin peptide for
inhalation systemic delivery were coated with chitosan oligosaccharides (CH–OS) and polyvinyl alcohol (PVA,
anionic emulsifier with hydrophobic anchor) were tested in vitro against A549 and in vivo rat lung to show enhanced
electrostatic interaction with the cell line for the former and reduced for the later. However in vivo, both showed lon‐
ger residence time but CH–OS liposome had interacted with the membrane causing membrane damage and opening
formation with faster peptide absorption. Furthermore, the PVA-liposomes showed a more sustained release profile
(Murata et al. 2012).
Ag NPs of different sizes and surface coatings were tested in a series of in vitro and in vivo experiments (Silva
et al. 2015). Ag NPs of size 20 nm and 110 nm and coated with either citrate (C20, C110) or polyvinylpyrrolidone
(PVP) (P20, P110) were tested in vitro regarding their shedding of Ag + ions in media, and the cytotoxicity responses
against human bronchial epithelial (BEAS-2B) and murine macrophage cell (RAW 264.7). The findings showed fast‐
er dissolution of NP 20 nm size with Ag + ions productions with more cytotoxicity and oxidative stress induction
than NP 110 nm. In vivo comparisons have confirmed the findings where C20, C110, P20, P110 were administered
intratracheal single-dose exposure to a serial dose (0, 0.1, 0.5, 1 mg/kg body weight (BW) in male Sprague Dawley
rats. At day 1, 7, 21 postexposure, BALF, lung tissues were collected. All different sized particles had induced signif‐
icant acute inflammatory polymorphs infiltrations which were clearly manifested in the BALF on days 1 and 7 and
persistent to 21 days for higher doses of 0.5 and 1 mg/kg BW. At higher doses, the lungs showed patchy centriacinar
infiltration of inflammatory cells such as neutrophils, monocytes and macrophages, necrotic cells and cellular debris
that gradually resolved by day 21, but higher doses of NP110 showed persistent cellular infiltrations and debris until
day 21. BALF showed higher levels of LDH, protein content, neutrophil count, and inflammatory cytokines. This
indicated the smaller size NPs had faster dissolution than larger particles. Another in vivo study compared the above
male Sprague Dawley (SD) rats exposure to Brown-Norway (BN, asthma and allergic lung model) rats to same single
exposure to Ag NPs C20, P20, at a dose of 0.1 mg/kg BW (Seiffert et al. 2015). Both had developed inflammatory
lung response, but the BN rats showed eosinophilic allergic and neutrophilic type of inflammation with higher protein
content and oxidative stress markers while SD rats showed more neutrophilic inflammation with high levels of cyto‐
kines. The response was severe for the C20 than P20, suggesting that the PVP had a role in neutralizing or reacting
with the Ag NP. These studies illustrated the effect of NP size, surface area, coating, and animal species on the NP
cytotoxicity.
The protein corona rendered positive polymeric and some metal NPs a negative charge with a loss of the mem‐
brane depolarizing effect abolishing the hemolytic effect (Cho et al. 2014). It was previously mentioned, the protein
corona might limit the effect and/or increase the NP toxicity by masking the charge, increasing the aggregation, en‐
hancing the macrophages uptake and initiating inflammation and immune response.
Shielding the NPs is a mechanism where the NPs are covered with hydrophilic polymers, commonly PEG, to limit
the protein adsorption. PEGylated NPs for drug delivery show more stable and longer shelf-life formulations. In vitro
PEGylated NPs showed lower ROS productions and reduced cytotoxicity than non-PEGylated NPs (Bhattacharjee
et al. 2013). PEG NPs showed in vivo enhanced bioavailability, reduced immune recognition, longer circulatory half-
life and reduced renal clearance (Vij et al. 2010). Another study showed the size and the density of PEG coating had
increased the circulatory life of micelles in mice (Wang et al. 2015). Quartz NPs with the surface negatively charged
by coating showed less particle uptake and inhibition of the oxidative DNA damage in A549 cells compared with the
non-coated quartz NPs (Schins et al. 2002). Negatively charged liposomes showed longer blood circulation in com‐
parison to the neutral liposomes, with the positively charged liposomes showing faster clearance and higher toxicity
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(Bourquin et al. 2018). Silver NPs of 15 nm size was coated with Polysaccharides (PS) and hydrocarbon (HC). PS
and HC showed different agglomeration pattern and morphology when dispersed into the alveolar lining and lysoso‐
mal fluids. The PS coated silver NPs showed de-coating after dispersion (Braydich-Stolle et al. 2014). Three types of
amorphous Silica NPs (unfunctionalized, amine or positively coated, carboxylate or negatively coated) were tested in
vitro against A549 in presence and absence of bovine lung surfactant Alveofact. The presence of lung surfactant in‐
creased the toxicity of unfunctionalized and amine functionalized silica NP whilst no change was observed for the
carboxylated silica NP and was associated with an increase in the IL-8 production irrespective to the presence or ab‐
sence of the surfactant. This was explained by the reactivity of the silanol (Si–O–H) group formed with the addition
of lung surfactant (Kasper et al. 2015).
Mucoadhesive or penetrative coatings have major influences on the aerosol deposition, retention, and toxicity.
Schneider et al. studied the effect of surface coating with mucoadhesive properties (MAP) or mucopenetrating prop‐
erties (MPP) using polystyrene NPs in ex vivo models and in vivo mouse models. MAP NPs showed increased entrap‐
ment within the mucous layer, aggregation and subsequent clearance, regardless of their size. MPP NPs up to a size
of 300 nm (after this, entrapment by the mucous mesh networks) showed better uniform lung distribution and en‐
hanced retention. The NPs were loaded with dexamethasone and studied again in vivo concluding the superior effects
of the MPP NPs over the MAP NPs and the free drug in reducing acute inflammatory mouse lung model (Schneider
et al. 2017). Surface hydrophobicity is another critical factor where it determines the pace of NPs crossing to the
underlying epithelial layers and affect the efficiency of the surfactant layer (Hu, Jiao, et al. 2013). In vitro study had
evaluated the interaction of the NPs with the protein content of the lung surfactant layer where magnetite NPs were
functionalized by either hydrophilic starch or hydrophobic phosphatidylcholine, both of negative charge. The hydro‐
phobic component of the used lung surfactant (SP-A) was adsorbing to the lipophilic NP, whereas the hydrophilic
(SP-D) surfactant proteins were adsorbing to the hydrophilic NPs. Herein was observed an increase in the macro‐
phages uptake of the hydrophobic NPs evidencing the protein corona role in the NP clearance (Ruge et al. 2012).
Hydrophobicity modification by coating Au NPs with peptides/or amino acids can dramatically limit or enhance the
cellular uptake (Mu et al. 2014).
MWCNTs had showed increasing the fibrogenic nature with the increase in their hydrophobicity. Other rare earth
oxides (REOs) that might be involved in environmental lung exposure were shown to be unstable in the acidic or
lysosomal media undergoing dissolution and releasing toxic ions that increase their toxicity. REOs and their ions re‐
act with the membrane phosphate groups destabilizing the cell membrane, organelle damage, leaking of lysosomal
enzymes and mitochondrial shut down, oxidative stress, NLRP3 inflammasome activation, pyroptosis, and induce au‐
tophagy cell death (Li, Ji, et al. 2014, Xia et al. 2016).
The amount of protein participating in NP corona formation with the lung fluid was investigated by Raesch and
his group using swine lavage lung surfactant. Magnetite NPs was functionalized with three different coatings (phos‐
phatidylcholine; (lipophilic NP), PEG5000; Hydrophilic PEG NP), and PLGA coating (PLGA NP). The lipid adsorp‐
tion to NPs was the smallest to PEG NP and the highest to lipid NP. The proteins were more than 300 types identified
on the surface of the NPs, with selectivity of SP-A and SP-D adsorption for lipophilic to hydrophilic NPs. Further
details and the limitation of the study could be found in this source (Raesch et al. 2015).
4.5.3. NP morphology
The shape of the NPs is another cytotoxic factor affecting the membrane vesicle formation, cellular uptake and
digestion, circulatory retention and distribution. NP shape can vary from rounded or oval spheres, ellipsoids, wires or
rods, cubes, sheets, cylinders and many others. Generally, the spherical NPs are considered to be safer and faster to be
endocytosed than rod- or fiber-like NPs. Spherical NPs can be deposited in the lung via different mechanism such as
impaction, settling or diffusion, but the longer aspect or fiber-like NPs are deposited by interception. Pal et al. investi‐
gated the shape-dependent cellular interactions for silver NPs where the cellular uptake of spherical NPs showed fast‐
er internalization compared to rod NPs (Vij et al. 2010). The fiber-like NPs cause macrophages frustration with in‐
crease in the inflammation potential and carcinogenicity, i.e, asbestos. TiO2 fiber NPs with 15 mm length had higher
toxicity compared to shorter 5 mm fibers with more persistent lung inflammation in mice. The SWCNT with a rod-
like shape showed higher pulmonary cytotoxic potential compared to spherical (Gatoo et al. 2014). Needle-shaped
NPs caused endothelial cell membrane disruption compared to spherical NPs. Non-spherical polymeric NPs showed
reduced cell internalization (Mu et al. 2014). SWCNTS were more effective in calcium channel blocking than spheri‐
cal fullerenes. Hydroxyapatite NPs with different shapes (sphere, needle, plate, rod) were tested against BEAS-2B
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cells, showing plate and needle shapes were more toxic than the others and this was related to their direct contact cell
damage. Graphene nanosheets were investigated and found to cause direct cell membrane damage due to its adsorp‐
tion ability that was reduced with increasing serum level concentration in the media. This confirmed the role of pro‐
tein coronas in reducing the toxicity (Zhao et al. 2013). Recent studies compared the same NPs with different shapes
and the resultant cytotoxicity and showed nanowires were more toxic compared to the others. Rare shapes such as
filamentous-, worm-, needle-, disc, or ring shaped are gaining popularity for drug delivery applications and may be‐
come the next generation drug delivery carriers, though at present, the traditional spherical NPs seems the safe deliv‐
ery carriers for lung and most of the delivery applications (Truong et al. 2015)
4.5.4. Nanoparticle chemistry, crystal structure, composition, and dissolution
The chemistry of the NPs has cytotoxic implications; affecting the rate of cellular uptake, internalization, ability to
produce oxidative stress and cell death (Xia et al. 2006). Different chemistry (Xia et al. 2008) and crystal structure
(Braydich-Stolle et al. 2009); show different potential in cytotoxicity, ROS production, and inflammation (Mu et al.
2014). For example, TiO2 (a common sunscreen NPs) rutile and anatase are allotropes of the same chemical composi‐
tion but different crystal structures. Rutile NPs showed more toxicity evaluated by ROS production, membrane depo‐
larization, DNA damage than the anatase NPs. The crystal structure affects the aggregation properties where in vitro
study showed anatase NPs soft and smaller aggregates were more internalized than hard bigger size rutile NPs aggre‐
gates (Gatoo et al. 2014). Impurities or any leftover solvents after the NPs manufacturing might play a role in their
cytotoxicity (Forest, Vergnon, and Pourchez 2017). The chemical properties that affect the particle solubility and bio‐
degradability should be considered to achieve biodegradable and avoid bio-resistant/bioaccumulating NPs. To what
extent, the bio-resistant particles could affect the lungs is still currently a gap in knowledge where chronic studies
might help to clear (Jeong et al. 2011). The NPs dissolution ability influences their toxicity. NPs are either easily
soluble/degradable or poorly soluble. The poorly soluble or more persistent NPs after the inhalation might predispose
to increase the inflammation and lung toxicity. Dissolved NPs can easily escape to the blood and spread to internal
organs and cleared by the kidneys. The more persistent NPs will be retained and cleared by mucociliary and macro‐
phages clearance to be distributed later to RES organs, liver drainage to GIT and cleared by feces. International Com‐
mission on Radiological Protection (ICRP) classified the NPs into three classes depending on their ability of dissolu‐
tion: Soluble material with retention half time <10 days, partly soluble within 10 to 100 days, and poorly soluble NPs
over 100 days. Other factors depends on dissolution especially with the metallic NPs are the ability to release toxic
ions, for example, Ag, Zn, etc (Xia et al. 2016).
4.5.5. Nanoparticle aggregation
The aggregation of NPs is another property that depends upon other NPs characteristics and the dispersing media.
It needs to be considered to understand the poor correlation between different toxicity studies, i.e. inhalation or instil‐
lation or in vitro studies. The aggregation of NPs could play a double effect; it could increase the NPs uptake as larger
amounts and more particles will sediment on the cellular surface (Limbach et al. 2005), or it could reduce the cellular
uptake if the aggregates are bigger than cellular size to permit the uptake (Drescher et al. 2011). In vivo it may play an
effective role in reducing their toxicity due to easier macrophages clearance (Takenaka et al. 2001). The aggregates
might increase the retention of NPs either in the lung or RES exerting increase in the inflammation and fibrosis (Ga‐
too et al. 2014).
4.5.6. Repeated dose exposure and bioaccumulation
The repeated lung exposure might happen in both environmental and occupational settings where small doses de‐
posited and might accumulate inducing chronic effects. Some studies tried to mimic chronic exposure by repeated
short-term exposure and showed persistent cell damage. Animal studies with doses near the occupational values
showed variable degree of lung damage. The bioaccumulation for NPs is not aimed therapeutically (Pietroiusti et al.
2018).
4.5.7. Other physicochemical properties
NP elasticity, porosity, chirality, bandgap, electrical, optical and magnetic properties (Han et al. 2019; Vallabani,
Singh, and Karakoti 2019) among many other factors that will have an influence on the design of NPs, loading, effi‐
ciency of the carrier, cytotoxicity, delivery method, the desired application, and therapeutic performances. Due to the
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novelty of NPs, there is limited literature discussing the cytotoxicity for lung delivery based on these factors, howev‐
er, the rapidly evolving field will uncover their potentials and hazards.
4.5.8. The dose-dependent toxicity
From the previous knowledge, it can be concluded that the mass dose of the NPs is not alone responsible for the
toxicity as the conventional parent bulk molecules where the interpretation of the physicochemical factors induced
toxicity should be considered.
In vitro and in vivo nanotoxicology studies have shown conflicting results regarding the dose-dependent NP toxici‐
ty. The nanotoxicology and inflammation studies are usually conducted with large NP doses, and any material at a
high dose could be toxic for the living organisms. Therefore, discrimination between test conditions should be con‐
ducted within the range of the aimed therapeutic doses. However, a large piece of information regarding the long-
term NP exposure or the bioaccumulation is still unknown (Takenaka et al. 2001). Detailed thorough physicochemical
NP characterization and systematic nanotoxicology evaluation of their properties are prerequisites prior to their appli‐
cations.
5. Nanotoxicology assessment methods
For nanotoxicological evaluation, NPs biocompatibility must be confirmed by two methods; in vitro then progress
into the in vivo methods (Table 6) prior to clinical trials. There are different methods that are increasingly getting
more popular in the research communities, i.e. ex vivo, and in silico methods. Prior to NP testing, thorough physico‐
chemical characterization of NPs is a must (Donaldson et al. 2009, Wu, Zhang, and Watanabe 2011). This allows
better understanding, easy comparability of different studies, and correlating the NP physicochemical characters with
their toxicity or biological profiles that helps better optimization for nano-medical applications (Sayes and Warheit
2009).
Table 6. Summary of advantages and limitations of the different assessment methods.
Assessment method Advantages Limitaions
• In vi‐
tro
• Initial faster screen
• High throughput screen
• Easy to perform
• Easy laboratory control
• Easier dosing
• Immortal continuous cell
lines
• Mechanistic and toxicity
studies
• Permeability and uptake
studies
• Non-animal alternative
• Not physiological represen‐
tative
• Lack of multicellular inter‐
actions
• Difficult to translate in vivo
• Short term exposure
• Lack of standardizations
• Difficult to compare between
different studies
• Variations between primary




• Relatively controlled and
easy dosing
• Better multicellular and or‐
gan response
• Mechanistic and toxicity
study
• Lack of biodistribution data
• Difficult to maintain and
handling
• Short term exposure
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Assessment method Advantages Limitaions
• In
vivo
• Whole body exposure
• Biodistribution data
• Single or repeated exposure
• Acute or chronic toxicity
• Short term and long-term
studies
• Training and handling
• Expensive and technically
demanding








• Predictive ability for mech‐
anistic and toxicity
• No animal cruelty
• Computer-based studies
• The availability of enough
information that enables the
study
• Lack of experiments stand‐
ardizations makes it difficult
to compare different results
5.1. In vitro methods
Cell-based toxicological screening is the first step prior to in vivo toxicological evaluation. They are commonly
known as cell culture or tissue culture methods. They provide an initial rapid, less costly, and non-animal assessment
of NPs. These assessments are very desirable both ethically and economically with better control over the test condi‐
tions, allowing wide range of concentrations, single or multiple parameters, and types of NPs to be tested (Frohlich
and Salar-Behzadi 2014; Warheit 2018). The most common endpoints are the cellular uptake, internalization and in‐
tercellular transport, membrane potential, mitochondrial function, effects on the cytokines or chemokines and cell sig‐
naling, oxidative stress (ROS or RNS), cell death and apoptosis, gene regulation and toxicity. The goal of these meth‐
ods is to achieve a cell-NP interaction response that discriminates between the NPs compatibility versus toxicity
(Lewinski, Colvin, and Drezek 2008). These methods commonly employ an enzyme-linked assay with final read-out
by fluorometric or spectrometric detectors. Other methods are through special stains and dyes and evaluated under
microscopy and flow cytometry. The cells are usually exposed to NP dispersions within a variable range of time (few
hours up to 2 or 3 days) then processing the cells for the endpoint results (Wu, Zhang, and Watanabe 2011, Joris et al.
2013). For example, a group of tests including the Alamar Blue, Tetrazolium, Neutral Red, Trypan blue-based assays
that are used to detect general toxicity of NPs, LDH assay to detect membrane potential, DCF Fluorescence assay,
lipid peroxidation or Glutathione assay to detect the oxidative stress potential. Inflammatory response can be assessed
using ELISA kits screening a variety of cytokines and chemokines. Genotoxicity assessed by using micronucleus,
COMET, and chromosomal aberrations tests (Jones and Grainger 2009; Drasler et al. 2017; Savage, Hilt, and Dziubla
2019).
The choice of the cell is usually dependant on the aimed target tissue, the route of administration, and the intended
application. Types of cells used are either primary or secondary cell lines. The secondary cell lines are a genetically-
transformed immortal cell line, hence called continuous or cancerous cell line. They are more widely used and com‐
mercially available from many vendors, i.e. American Tissue Type Culture Collection (ATCC). They provide easier
experimental handling and maintenance, faster growth and shorter experiment time. The primary cell lines are a har‐
vest of a target tissue on special plates with nutritional media. They are more challenging in isolation, differentiation
and phenotyping, maintenance, and special experimental and ethical requirements. As a result, their use is very ex‐
pensive and onerous testing but more closely representative for the in vivo counterparts. The 2 D monoculture is a
single and classic cell culture model and commonly lacks the multiple cell interactions and cross communications.
The co-cultures of different cell lines for example, lung epithelial cells with macrophages could provide more accu‐
rate results by the resemblance of the different cell mixture within the lung tissue. 3 D models have closer representa‐
tion of a mixture of different cell types within the tissue and provide the cell-cell interaction and communication with
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enhanced in vivo correlated results (Hughes et al. 2007, Jones and Grainger 2009). 3 D co-culture models known as
spheroids or organoids are grown in a 3 D scaffold made of inert materials as collagen, matrigel®, or others, supple‐
mented with stem cells or tissue cell mixtures and stimulated by different stimuli to differentiate the cells into lung
structures. ‘’Organ on chip’’ or miniaturized lung and Microfluidic systems are another 3 D co-culture models where
the lung organoid is subjected to mechanical and physical factors mimicking the biological environment, i.e. biologi‐
cal-air interface. The advantages of these miniaturized lungs are the very controllable nature, reliable, more physio‐
logically relevant, and simulating biological environment with the ability to screen many drugs prior to in vivo (Iyer,
Hsia, and Nguyen 2015).
5.2. High-throughput screening methods
Recent advances in cell-based assays allow for toxicity and/or efficacy screening of multiple nanomaterials at mul‐
tiple concentrations with multiple cell lines, simultaneously. This expansion of experimental design is practically ena‐
bled through the miniaturization and multiplexing of the experimental apparatus and method by utilization of either
ultra-small 384-well cell culture plates or nanodrop sample chambers on a chip. The nanodrop assay setup allows for
different assays with suitable detection features (e.g. fluorescence, and luminescence) to be performed in a fraction of
the volume without the cell-activation or photometric effects of the culture plate since the cell culture is performed in
a self-contained drop. However, since cells are typically microns in size, nanodrops do not necessarily capture cells
themselves, only fluidic cellular exudate for assay and analysis. By assaying numerous material types/functionaliza‐
tion’s and material concentrations on numerous cell types, all in parallel, complex interactions between materials and
cells may be ascertained through complex data analysis that correlates phenotypes with multi-well plates, cell culture,
detection schemes, and recognition schemes (Lemaire et al. 2007, Jan et al. 2008, Jones and Grainger 2009, Savage,
Hilt, and Dziubla 2019).
5.3. The main shortcomings for in vitro cell models in evaluating the inhaled NPs
Besides the inherent limitations of in vitro cell lines (Table 6), the exposure to NPs is assessed under submerged
conditions which is well-proven for many chemicals but when it comes to assess airborne NPs, it is unrealistic and
not comparable to the in vivo air liquid interface (ALI) exposure. Moreover, the NPs physicochemical properties can
be altered when dispersed in biological media prior to testing, limiting the translation to the in vivo setting. Hence,
ALI exposure systems are being developed and described in many studies (mostly in-house development) to enhance
their reliability, relevance, reproducibility, and predictability. Different mechanisms of spray/aerosolization are being
developed to generate NPs droplets that can be deposited on the cell layers by similar deposition mechanisms as in
the real inhalation exposure, i.e. impaction, gravitational settling, electrostatic deposition, diffusion.Furthermore, the
dosing and the dosimetry definition with poor translation from in vitro mass or number concentration into in vivo
surface area needs to be considered and applied. For assessing the lung/or inhalation exposure, the biological re‐
sponse is a strong cross communication between the different types of cells within the lung (that could be up to 40
different cell types) indicating the need of co-culture models under ALI. This should not underestimate the value of
the in vitro cell lines as a fast screening, inexpensive, and mechanistic approach, but more enhancement is needed.
Further details regarding ALI considerations, challenges and improvement can be found in the following sources
(Paur et al. 2011; Lacroix et al. 2018; Upadhyay and Palmberg 2018; Ihalainen et al. 2019).
5.4. Ex vivo methods
These methods employ viable animal tissues or whole organs while their structure maintained under simulated nat‐
ural conditions. Either these tissues or organs obtained from humans, e.g. in vitro skin absorption test (OECD TG
428), or animals sacrificed for any other cause excluding the need for the experiment, e.g. slaughterhouse (isolated
Chicken Eye test; OECD TG 438) (Rasmussen et al. 2019). Ex vivo models evaluate NP uptake, distribution, and
toxicokinetics. They provide conditions that are realistic and mimic the in vivo response, and more control over ex‐
perimental conditions. For example, ex vivo lung slices from either human or rat or mouse are used to assess the res‐
piratory system for various types of NPs to detect cytotoxicity, oxidative stress, genotoxicity, alteration of protein
expression, or inflammation (Rasmussen et al. 2019). The use of ex vivo studies is new and some variations are there
preventing their standardizations (Wick et al. 2015). Moreover, the inability to relate the appropriate dose to the in
vivo studies remains a challenge. Despite their novelty, these promising studies can provide very complex and realis‐
tic information about the NPs uptake, transport and mechanism of action.
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5.5. In vivo methods
Inevitably, the in vivo studies will follow the in vitro experiments to validate a range of realistic NPs doses on 
animals. In vivo animal studies provide more consistent clues for uncovering the NPs kinetics, and understanding of 
the biological exposure-response, dose-range, and toxicity to support the subsequent human clinical trials. Some con‐
cerns arise when testing the NPs in vivo, first, the dose is difficult to translate from in vitro doses to the in vivo 
animals where it is not uncommon for in vitro experiments to have very high toxic dose ranges (Oberdorster and 
Kuhlbusch 2018). The complexity of NPs that can alter the kinetic behavior according the different route of adminis‐
tration requires a specific administration model for each route. The main disadvantages, the issues of interspecies var‐
iability; where the lung of mice, or rats is much smaller and less complex compared to human lung, the difficulty in 
real time bioanalytical assessments of NPs in vivo (Saifi, Khan, and Godugu 2018; Zhao et al. 2019).
Registration, Evaluation and Administration of Chemicals (REACH) regulations were adopted for NPs evaluation 
even though they are different from bulk chemicals. ''When assessing nanotoxicity in vivo, the following aspects 
ought to be evaluated according to REACH guidelines: acute, subchronic and chronic toxicity, skin and eye irritation 
or corrosion and skin sensitization, genotoxicity, reproductive toxicity, carcinogenicity and the NPs toxicokinetics 
(Joris et al. 2013). Full documentation of the experiment from animal behavior, food and water intake, samples of 
blood, urine and histopathological specimens of target and other organs, with the toxicity endpoints must be collec‐
ted. Further tissue organ slices can be used for in vitro experiments to get more detailed and representative assays (ex 
vivo) (Joris et al. 2013).
5.6. In silico methods
The use of computer-based programs that use huge piece of available data to predict the NPs toxicity. Quantitative 
structure-activity relationships (QSAR) are rapidly evolving approaches that need developing for the exceptional 
characteristics of NPs that are different from their conventional chemical counterparts (Myatt et al. 2018). The aim of 
these models is to provide very accurate models with pre-set standard of parameters that predict and link the NPs 
based on their physicochemical characteristics and their potential bioactivity, behavior, and toxicity (Nel et al. 2013). 
For example, QSAR models have been developed on physicochemical characters (Wagner 2018 or pharmaco‐kinetic 
models based on in vitro and/or in vivo data (Rodrigues et al. 2018), environmental behavior models (Lin et al. 
2018), e.g. mode of transport and fate. A study by Gupta et al. had successfully predicted the in vitro cytotoxici‐ty of 
five different NPs based on their physicochemical characters (Yan et al. 2017). In silico models are yet to be 
validated for the NPs models even though they are validated by the OECD guidance for conventional chemical test‐
ing (Suzuki et al. 2017; Qiu, Clement, and Haynes 2018; Rasmussen et al. 2019). Successful QSAR models are in 
need for data availability of accurate and consistent grouping of NPs based on physicochemical characters, mecha‐
nisms of action, exposure scenarios, standardized in vitro and in vivo testing conditions. This is a big challenge as of 
the NPs novelty and changeability. Furthermore, the availability of these models remains another challenge, as not 
much is known about how to build up these models and what parameters needed. Sharing and reporting data have 
mutual benefit to close the gaps in NP knowledge (Joris et al. 2013; Raies and Bajic 2016; WHO 2018).
6. Conclusion
The fast-growing field of nanomaterials and its wide variety of applications in various fields of life requires urgent
needs of developing methods to efficiently assess their safety prior to marketing. With the increasing research evalu‐
ating the safety of the NPs, more understanding of the potential risks associated with their physicochemical properties
is emerging. The more detailed physicochemical characterization of NPs prior to their testing, the better understand‐
ing, easier comparability and conclusiveness the results are.
However, endless efforts from different regulatory bodies are there to set standards and protocols for NPs testing
and inhalation modeling exposures to help minimize any potential risks that might occur when any type of NPs are
employed, there are still many technical challenges as well as more need to implement and harmonize international
standardizations. Nanotoxicity assessments are currently evaluated in vitro prior to in vivo animal study. In vitro ex‐
periments are achieved under submerged conditions and highlight single-cell type-dependent response that lack the
whole body or whole organ cross communication response. Newer methods such as 3 D models, co-cultures, lung on
chip microfluidics, and testing under ALI provide more physiologically relevant models. In vivo methods suffer from
© Copyrights 2018
animal specificity when translated to humans in addition to their ethical issues and cost problems. Most of the nano‐
toxicology studies are performed under high doses that might not be realistic and more relevant doses and concentra‐
tions are required. Other models are being developed to enhance the relevance and reliability of the nanotoxicology
assessments such as ex vivo and in silico models that have shown many successful examples of correlation to in vivo
results.
Unfortunately, the scientific community had shown many discrepancies in their NPs experimentations and hence
urgent needs to harmonize standards and protocols for NPs testing. These protocols will ensure single profile of as‐
says that each NPs can be tested on and ensure more general acceptance of conclusive results.
NP pulmonary drug delivery has a very promising potential as noninvasive route that can deliver the drug locally
or systemically. Yet there are challenges, optimizing NPs formulation for lung delivery, full understanding of NP aer‐
osol fate and behavior after lung deposition, systemic behavior, and physicochemical properties and their effects on
the cellular interactions, NP retention, and biocompatibility. There are many studies evidenced that the dose and
physicochemical factors as size, shape, chemistry, etc, all play roles in NPs cytotoxicity. Various mechanisms could
be intersected for the same NPs cytotoxicity such as ROS, membrane depolarization, DNA damage, inflammation,
cell death. Assessment of unintentional lung exposure to NPs in different environmental and occupational settings as
well as from consumer products are still challenged with many technical and economic problems that require devel‐
opment of standards and protocols to assess their safety and set measures to control their environmental release and
public exposure. Many studies are needed to close the knowledge gap regarding the release from occupational set‐
tings and consumer products into the environment to build realistic quantitative exposure-risk assessments for NPs
safety.
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